NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

After October 13, 2022, this dataset will no longer be updated as the related CDC COVID Data Tracker site was retired on October 13, 2022.

This dataset contains historical trends in vaccinations and cases by age group, at the US national level. Data is stratified by at least one dose and fully vaccinated. Data also represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

While some studies have previously estimated lives saved by COVID-19 vaccination, we estimate how many deaths could have been averted by vaccination in the US but were not because of a failure to vaccinate. We used a simple method based on a nationally representative dataset to estimate the preventable deaths among unvaccinated individuals in the US from May 30, 2021 to September 3, 2022 adjusted for the effects of age and time. We estimated that at least 232,000 deaths could have been prevented among unvaccinated adults during the 15 months had they been vaccinated with at least a primary series. While uncertainties exist regarding the exact number of preventable deaths and more granular data are needed on other factors causing differences in death rates between the vaccinated and unvaccinated groups to inform these estimates, this method is a rapid assessment on vaccine-preventable deaths due to SARS-CoV-2 that has crucial public health implications. The same rapid method can be used for future public health emergencies.

Monthly Cumulative Number and Percent of Persons Who Received ≥1 Influenza Vaccination Doses, by Flu Season, Age Group, and Jurisdiction

• Influenza vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. More information about the IIS can be found at https://www.cdc.gov/vaccines/programs/iis/about.html.

• Influenza vaccination coverage estimate numerators include the number of people receiving at least one dose of influenza vaccine in a given flu season, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions’ data may include data submitted by tribes. Estimates include persons who are deceased but received a vaccination during the current season. People receiving doses are attributed to the jurisdiction in which the person resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. Influenza vaccination coverage denominators are obtained from 2020 U.S. Census Bureau population estimates.

• Monthly estimates shown are cumulative, reflecting all persons vaccinated from July through a given month of that flu season. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.

• Because IIS data contain all vaccinations administered within a jurisdiction rather than a sample, standard errors were not calculated and statistical testing for differences in estimates across years were not performed.

• Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction. More information on laws and policies are found at https://www.cdc.gov/vaccines/programs/iis/policy-legislation.html.

• Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for children (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-coverage-race.html) and adults (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html) because NIS estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations, and quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.

Importance: COVID-19 vaccine development has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. Objective: To examine the factors associated with survey participants’ self-reported likelihood of selecting and receiving a hypothetical COVID-19 vaccine. Design, Setting and Participants: A survey of a nonprobability convenience sample of 2000 recruited participants including a choice-based conjoint analysis was conducted to estimate respondents’ probability of choosing a vaccine and willingness to receive vaccination . Participants were then asked to evaluate their willingness to receive each vaccine individually. The survey presented respondents with 5 choice tasks. In each, participants evaluated 2 hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, vaccine B, or neither vaccine . Vaccine attributes included efficacy, protection duration, major side effects, minor side effects, US Food and Drug Administration (FDA) approval process, national origin of vaccine, and endorsement. Levels of each attribute for each vaccine were randomly assigned and attribute order was randomized across participants. Survey data wereas collected on July 9, 2020. Main Outcomes and Measures: Average marginal component effect sizes and marginal means were calculated to estimate the relationship between each vaccine attribute-level and the probability of the respondent choosing a vaccine and self-reported willingness to receive vaccination . Results: A total of 1,971 US adults responded to the survey (median age 43; IQR: 30 to 58); 999 (51%) were women, 1,432 (73%) White, 277 (14%) Black, and 190 (10%) Latinx. An increase in efficacy from 50% to 70% was associated with a higher n increased the estimated probability of choosing a vaccine ofby .07 [95% CI: .06 to .09]; and an increase from 50% to 90% was associated with a higher probability of choosing a vaccine of .16 [95% CI: .15 to .18]. An increase in protection duration from 1 to 5 years was associated with a higher probability of choosing a vaccine of .05 [95% CI: .04 to .07]. A decrease in the incidence of major side effects from 1 in 10,000 to 1 in 1,000,000 was associated with a higher probability of choosing a vaccine of .07 [95% CI: .05 to .08]. An FDA emergency use authorization was associated with a lower probability of choosing a vaccine of -.03 [95% CI: -.01 to -.04] compared with full FDA approval. A vaccine that originated from a non-US country was associated with a lower probability of choosing a vaccine [China: -.13 (95% CI: -.11 to -.15 UK: -.04 (95% CI: -.02 to -.06)]. Endorsements from the US Centers for Disease Control and Prevention [.09 (95% CI: .07 to .11)] and World Health Organization [.06 (95% CI: .04 to .08)], compared with an endorsement from President Trump, were associated with higher probabilities of choosing a vaccine. Analyses of participants’ willingness to receive each vaccine when assessed individually yield similar results. Efficacy was the most important factor. An increase in efficacy from 50% to 90% was associated with a 10% higher marginal mean willingness to receive a vaccine [.51 to .61]. A reduction in the incidence of major side effects was associated with a 4% higher marginal mean willingness to receive a vaccine [.54 to .58]. A vaccine originating in China was associated with a 10% lower willingness to receive a vaccine versus one developed in the US [.60 to .50] Endorsements from the CDC and WHO were associated with substantial increases in willingness to receive a vaccine, 7% and 6%, respectively , from a baseline endorsement by President Trump [.52 to .59; .52 to .58]. Conclusions and Relevance: In this survey study of US adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self-reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction

• Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html).

• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.

The goal of the Monthly Outcome Survey (MOS) Small Area Estimations (SAE) is to generate estimates of the proportions of adults, by county and month, who were in the population of interest for the U.S. Department of Health and Human Services’ (HHS) We Can Do This COVID-19 Public Education Campaign. These data are designed to be used by practitioners and researchers to understand how county-level COVID-19 vaccination hesitancy changed over time in the United States.

Monthly Cumulative Number and Percent of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses, by Age Group, and Jurisdiction, United States

  Description

• Monthly Cumulative Percent of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses, by Age Group and Jurisdiction • COVID-19 vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly… See the full description on the dataset page: https://huggingface.co/datasets/HHS-Official/monthly-cumulative-number-and-percent-of-persons-w.

Context

After observing many naive conversations about COVID-19, claiming that the pandemic can be blamed on just a few factors, I decided to create a data set, to map a number of different data points to every U.S. state (including D.C. and Puerto Rico).

Content

This data set contains basic COVID-19 information about each state, such as total population, total COVID-19 cases, cases per capita, COVID-19 deaths and death rate, Mask mandate start, and end dates, mask mandate duration (in days), and vaccination rates.

However, when evaluating a pandemic (specifically a respiratory virus) it would be wise to also explore the population density of each state, which is also included. For those interested, I also included political party affiliation for each state ("D" for Democrat, "R" for Republican, and "I" for Puerto Rico). Vaccination rates are split into 1-dose and 2-dose rates.

Also included is data ranking the Well-Being Index and Social Determinantes of Health Index for each state (2019). There are also several other columns that "rank" states, such as ranking total cases per state (ascending), total cases per capita per state (ascending), population density rank (ascending), and 2-dose vaccine rate rank (ascending). There are also columns that compare deviation between columns: case count rank vs population density rank (negative numbers indicate that a state has more COVID-19 cases, despite being lower in population density, while positive numbers indicate the opposite), as well as per-capita case count vs density.

Acknowledgements

Several Statista Sources: * COVID-19 Cases in the US * Population Density of US States * COVID-19 Cases in the US per-capita * COVID-19 Vaccination Rates by State

Other sources I'd like to acknowledge: * Ballotpedia * DC Policy Center * Sharecare Well-Being Index * USA Facts * World Population Overview

Inspiration

I would like to see if any new insights could be made about this pandemic, where states failed, or if these case numbers are 100% expected for each state.

BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufactured MVA production lots, and to confirm the safety and tolerability of MVA focusing on cardiac readouts.MethodsThe trial was conducted at 34 sites in the US. Vaccinia-naïve adults aged 18-40 years were randomly allocated to one of four groups using a 1:1:1:1 randomization scheme. Subjects received either two MVA injections from three consecutive lots (Groups 1-3), or two placebo injections (Group 4), four weeks apart. Everyone except personnel involved in vaccine handling and administration was blinded to treatment. Safety assessment focused on cardiac monitoring throughout the trial. Vaccinia-specific antibody titers were measured using a Plaque Reduction Neutralization Test (PRNT) and an Enzyme-Linked Immunosorbent Assay (ELISA). The primary immunogenicity endpoint was Geometric Mean Titers (GMTs) after two MVA vaccinations measured by PRNT at trial visit 4. This trial is registered with ClinicalTrials.gov, number NCT01144637.ResultsBetween March 2013 and May 2014, 4005 subjects were enrolled and received at least one injection of MVA (n = 3003) or placebo (n = 1002). The three MVA lots induced equivalent antibody titers two weeks after the second vaccination, with seroconversion rates of 99·8% (PRNT) and 99·7% (ELISA). Overall, 180 (6·0%) subjects receiving MVA and 29 (2·9%) subjects in the placebo group reported at least one unsolicited Adverse Event (AE) that was considered trial-related. Vaccination was well tolerated without significant safety concerns, particularly regarding cardiac assessment.ConclusionsThe neutralizing and total antibody titers induced by each of the three lots were equivalent. No significant safety concerns emerged in this healthy trial population, especially regarding cardiac safety, thus confirming the excellent safety and tolerability profile of MVA.Trial registrationClinicalTrials.gov NCT01144637

Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States

• Since 2019, CDC has been exploring use of data obtained from (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices. These data are being presented publicly for the first time this season; further evaluations of these data are underway.

• The pharmacy data include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office data are claims based.

• The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.

• Vaccinations administered in other settings such as workplaces and community settings are not included in these data.

• Weekly Number of Influenza Vaccinations Administered, in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims.